GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th

─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2024 financial results and provided a business update. "I am proud of the Hyperfine team, achieving record revenue and delivering meaningful progress across innovation and clinical initiatives in the quarter," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "The opportunities ahead

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. Abou

GUILFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales across US and international accounts, as well as the important milestones we hit in Q1 by commencing CARE PMR study enrollment in Alzheimer's and launching our 8th generation AI-powered software," said Maria Sainz, Chief Executive Officer and President of Hyperfin

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the

GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2023 financial results and provided a business update. "I am pleased with our strong growth in 2023. We continued to drive adoption in our beachhead markets of critical care and pediatrics, and we made significant progress to expand our use cases through clinical evidence and innovation," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "We remain focused on our 3

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the st

GUILFORD, Conn., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 financial results and provided a business update. "We remain focused on our three strategic pillars of innovation, clinical evidence, and commercialization, all while actively managing our spending, resulting in meaningful progress in the transformation of the business," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "The quarter was dominated by U.S. di

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2023 on Thursday, November 9, 2023. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. Abo

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

Intersocietal Accreditation Commission (IAC)'s release of new standards accepting ultra-low-field MRI technology enables accredited facilities to qualify for reimbursement from the US Centers for Medicare & Medicaid Services (CMS). Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the issuance of new MRI standards by the Intersocietal Accreditation Commission (IAC), a leading CMS-approved accrediting body. The new standards, effective immediately, now include portable MR scanning at the point of care. This press rele

The breadth of data being presented at the premier radiology meeting of 2024 illustrates the increasing relevance of portable, ultra-low-field MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that ten scientific abstracts highlighting ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. For Hyperfine, this marks the largest number of presentations at RSNA to date, underscoring the growing interest in and expanding applications

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming BTIG Digital Health Forum on Monday, November 25, 2024. Management will also participate in the Mizuho Healthcare Conference in New York, NY, on Wednesday, December 11, 2024. To schedule a one-on-one meeting with management, please reach out to your BTIG representative, Mizuho representative, or the investor contact below. About the Swoop® Portable MR Imaging® System The Swoop® Portable MR Imaging® system is U.S. Food and Drug Admin

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

CE approval of the latest generation Swoop® system software is a significant milestone in Hyperfine's international strategy, allowing broader European commercial expansion. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced CE approval of its latest generation of AI-powered Swoop® system software under the European Medical Device Regulation (MDR, EU No. 2017/745). This approval marks a significant step in positioning Hyperfine for broad European launch of the Swoop® Portable MR Imaging® system, enabling faster, high-qu

Today's presentation at CTAD, a leading international Alzheimer's conference, expands research supporting the value of ultra-low-field MRI in monitoring amyloid-related imaging abnormalities (ARIA). Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of additional research data and images using the Swoop® system to image patients with Alzheimer's disease who are part of the observational, investigator-initiated CARE PMR study. This press release features multimedia. View the full release here: https://ww

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th

The SAFE MRI ECMO study evaluated the use of ultra-low-field portable MR imaging on ICU patients undergoing extracorporeal membrane oxygenation (ECMO) with an elevated risk of acute brain injury (ABI) Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today congratulates investigators at Johns Hopkins Hospital and the University of Texas-Houston on the publication of an exciting study using the Swoop® system for patients on extracorporeal membrane oxygenation (ECMO) support. This press release features multimedia. View the full release

The Swoop® Portable MR Imaging® system shows faster time-to-scan compared to conventional MRI and good specificity in emergency stroke care Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of interim data supporting the role portable ultra-low-field MRI can play in acute stroke workup in a hospital emergency department setting. The findings from the study, titled Interim Analysis from Single Centre Observational Study of Ultra-Low Field Portable MRI in Acute Stroke Diagnostic Workup, were presented b

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a collaboration with the Medical University of South Carolina to assess the brains of astronauts before and after embarking on the Polaris Dawn mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240911316319/en/(Photo: Business Wire) Researchers will utilize the Swoop® Portable MR Imaging® system at a SpaceX facility in Florida to acquire detailed images of astronauts' brains within hours of their return

SC 13G - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13D/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13G - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13D - Hyperfine, Inc. (0001833769) (Subject)

10-Q - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

10-Q - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

10-Q - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

ARS - Hyperfine, Inc. (0001833769) (Filer)

The total number of Hyperfine AI-powered marketing authorizations places the company in a leading position on recently published FDA list.Hyperfine (NASDAQ:HYPR), the groundbreaking medical device company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system—today announced the clearance of the ninth generation of AI-powered Swoop® system software. This advanced software significantly reduces scan times across multiple MR sequences without sacrificing image quality. The U.S. Food and Drug Administration (FDA) clearance of this software further solidifies Hyperfine as a leader in AI-powered health technology.Thes

The publication includes a subset of data from the ACTION PMR stroke study and provides early evidence that the Swoop® system is a promising tool for enabling critical stroke treatment choices in urgent care settings.

Portable ultra-low-field MR brain imaging provides affordable and accessible technology that may help physicians monitor ARIA and Alzheimer's disease progression in diverse professional care settings.Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that two presentations on the clinical utility of portable ultra-low-field MRI for Alzheimer's disease monitoring have been accepted in the developing topics poster sessions at the upcoming 2024 Alzheimer's Association International Conference, July 28–August 1 in Philadelphi

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI marketHyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia.

Management expects cash burn for the full year 2024 to be approximately $40 million.  

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 17.65 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $3.295 million which beat the analyst consensus estimate of $3.053 million by 7.91 percent. This is a 25.05 percent increase over sales of $2.635 million the same period last year.

Study will assess the clinical utility and workflow benefits of physicians using images acquired by the Swoop® Portable MR Imaging® system to identify ARIA events in Alzheimer's patients treated with amyloid-targeting therapy

Gainers Biolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q4 earnings came out today. Terns Pharma (NASDAQ:TERN) shares rose 10.14% to $7.21. The company's market cap stands at $466.4 million. Aptevo Therapeutics (NASDAQ:APVO) stock increased by 9.37% to $4.9. The market value of their outstanding shares is at $2.6 million. Nexalin Technology (NASDAQ:NXL) shares increased by 7.62% to $0.48. The company's market cap stands at $3.4 million. Evolus (NASDAQ:EOLS) stock moved upwards by 7.61% to $14.84. The company's market cap stands at $912.6 million. Phio Pharm

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development Director Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with three experienced and accomplished distributors to support commercial expansion plans of the Swoop® system into European markets with an initial focus on France, the United Kingdom, and Italy. In 2023, Hyperfine, Inc. obtained CE certification under the EU MDR and UKCA certificati

BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) ("22nd Century" or the "Company"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, "Larry is a seasoned executive known for his 'hands-on' leadership style emphasizing teamwork, business alignment, continuous improvement, cost control and process optimization. His track record of success with fast growing public companies will serve 22nd Century well as it continues to execu

In addition to the study, the company appoints a world-class stroke advisory board as part of its acute ischemic stroke initiatives Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

GUILFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), creator of the Swoop® Portable MR Imaging System™, the world's first US FDA-cleared portable magnetic resonance imaging (MRI) device, announced today that it has completed registration and notification of the device in Australia and New Zealand. With this activity, the Swoop system is now available for purchase in Australia and New Zealand and includes the US FDA-cleared advanced reconstruction software using deep learning. Multiple pilot research units have been ordered across key Australian cities bolstering Hyperfine's entry into these two markets and laying the foundation for commercial efforts. Hyperfin

Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract's Head of Cardiovascular and Digital Health. This key role completes Tesseract's leadership team and coincides with a series of critical, strategic hires under the helm of CEO Vicky Demas, PhD. Dr. McConnell was brought on to leverage Tesseract's technology to guide the expansion of its cardiovascular strategy. In this role, he is poised to lead and champion the design, planni

GUILFORD, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Hyperfine Inc. (NASDAQ:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced the appointment of Dr. Chip Truwit as senior medical director. For more than 30 years, Truwit has committed his talents to clinical practice in public sector healthcare and neuroradiology education. "We feel privileged to welcome Dr. Truwit to the Hyperfine team," Khan Siddiqui, M.D., Hyperfine's chief medical officer and chief strategy officer, said. "His remarkable experience in neuroradiology and his work with underserved communities will make considerable contributions to the Hyperfine mission of in